Compare CVS Health Corp (CVS) vs Roundhill Magnificent Seven ETF (MAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Roundhill Magnificent Seven ETF — how do they compare? CVS Health Corp trades at $93.7 (market cap $122.36B), while Roundhill Magnificent Seven ETF trades at $68.42. The key difference: CVS Health Corp pays a 2.78% dividend while Roundhill Magnificent Seven ETF pays none, and Roundhill Magnificent Seven ETF is trading nearer its 52-week high, CVS Health Corp nearer its low. Which is the better fit depends on your goals.
| CVS | MAGS | |
|---|---|---|
Market Cap | $122.36B | — |
Sector | Health | Sector/Thematic |
52-Week High | $110.60 | $70.94 |
52-Week Low | $65.51 | $55.39 |
Enterprise Value | $184.71B | — |
Dividend Yield | 2.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
MAGS trades at $69.07, up 0.71% today, with a bullish technical signal from moving averages but neutral oscillators. Recent news highlights underperformance versus the S&P 500 and concerns over AI spending pressure on big tech balance sheets. The ETF has gained 181% since launch but faces challenges from equal-weighted concentration in the Magnificent Seven stocks.
The outlook is mixed: technical strength supports near-term upside, but fundamental risks from high AI capital expenditure and shifting investor sentiment toward broader market exposure pose headwinds. Investment opportunity hinges on AI revenue growth outpacing costs, while key risks include sector rotation and valuation compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Roundhill Magnificent Seven ETF
MAGS is an ETF that provides concentrated exposure to the seven technology-focused mega-cap companies often referred to as the 'Magnificent Seven' (Alphabet, Amazon, Apple, Meta, Microsoft, NVIDIA, and Tesla). The fund is designed to capture the performance of these market-leading stocks, which have been the primary drivers of market returns. It offers a simple way for investors to invest solely in this select group of high-growth technology companies.
Read more on MAGS →
